GlassScriptPhysician profile
Vijayakumar K Reddy
NPI 1932391547
$1,928.35
in general payments reported to CMS, 2019-2025
28 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $60.96 · 2021: $78.80 · 2022: $293 · 2023: $439 · 2024: $409 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329 · Education: $15.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,328.53 |
| Education | $15.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $408.72 | 2020-2024 | |
| Amgen INC. | $145.25 | 2023-2025 | Tavneos, Krystexxa, Parsabiv |
| Akebia Therapeutics INC | $139.75 | 2022 | |
| Vifor Pharma, INC. | $125.80 | 2019-2024 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $119.91 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $102.90 | 2022-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.11 | 2023-2025 | Jardiance, Cyltezo |
| Novo Nordisk INC | $80.41 | 2022-2025 | |
| Abbvie INC. | $78.80 | 2021 | |
| Glaxosmithkline, LLC. | $78.02 | 2023-2025 | Benlysta, Jesduvroq |
| Genentech USA, INC. | $67.91 | 2019-2024 | Actemra |
| Ardelyx, INC. | $66.98 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $66.13 | 2024-2025 | Tarpeyo |
| Corcept Therapeutics | $40.83 | 2023 | Korlym |
| Apellis Pharmaceuticals, INC. | $40.52 | 2025 | Empaveli |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eurofins Viracor, LLC | $39.99 | 2020 | |
| Insulet Corporation | $24.98 | 2024 | Omnipod |
| Scpharmaceuticals INC. | $24.86 | 2025 | |
| Xeris Pharmaceuticals, INC. | $24.24 | 2025 | Keveyis |
| Janssen Biotech, INC. | $22.43 | 2024 | Tremfya |
| Fresenius USA Marketing, INC. | $18.50 | 2024 | Velphoro |
| Dexcom, INC. | $17.45 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $17.34 | 2019 | |
| Eusa Pharma (US) LLC | $17.07 | 2022 | |
| Recordati_rare_diseases_inc. | $17.07 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.11 | 2025 | Ultomiris |
| Horizon Therapeutics Plc | $15.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijayakumar Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.